This week has been busy with several important updates in the pharmaceutical and healthcare industries. Here\u2019s what you need to know, explained in simple terms by a pharmacist:<\/p>\n
**New Lung Cancer<\/a> Treatment Approved in the U.S.** **Pharmaceutical Insights from Recent Events** **The Role of Drug Formulation in Treatment Success** **Why Digital Solutions Are Essential in Drug Manufacturing**
\nBayer has received an accelerated approval from the U.S. Food and Drug Administration (FDA<\/a>) for a new treatment called Hyrnuo (sevabertinib) for a specific type of lung cancer. This drug will now be available as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not squamous. The key detail is that it works for patients who have a specific genetic mutation called HER2 (ERBB2) tyrosine kinase domain-activating mutations. This type of cancer has a poor prognosis, so this approval is significant. Doctors will use an FDA-approved test to confirm if a patient\u2019s cancer has this mutation before prescribing Hyrnuo.<\/p>\n
\nThe healthcare industry has been buzzing with events and conferences, such as the European Society of Cardiology (ESC) Congress and the European Respiratory Society (ERS) Congress. Experts, including editors and reporters, have been sharing updates and discussing the latest trends in these fields. If you\u2019re interested in hearing about the key takeaways from these events, a new podcast has been released summarizing the most important findings. You can listen to it here:
\nhttps:\/\/lnkd.in\/efTnCFUH<\/p>\n
\nWhen it comes to developing new drugs, the way a medication is formulated\u2014meaning how it is designed and delivered\u2014can make a big difference. For example, switching from an intravenous (IV) injection to a subcutaneous (under-the-skin) injection can improve patient comfort and convenience. In pediatrics, taste-masked oral liquids can make medications easier for children to take. Similarly, biologics (medications made from living cells) that don\u2019t contain citrate can reduce side effects. These innovations can improve how well patients stick to their treatment plans, simplify how medications are given, and even lower<\/a> healthcare costs. A detailed article by Piramal Pharma Solutions explains how these formulation improvements are changing the way drugs are developed and used.<\/p>\n
\nDrug manufacturing must follow strict rules to ensure safety and effectiveness. However, using paper records or a mix of paper and digital records can create risks, such as errors in data or unclear records. Regulators are paying close attention to how work is done on the manufacturing floor, not just paperwork. Moving to fully digital systems for tasks like batch records, electronic device history records (eDHRs), and logbooks can help manufacturers stay compliant, speed up reviews, and be ready for audits. MasterControl explains why this shift is becoming necessary and how their digital manufacturing solutions can help.<\/p>\n